Results 151 to 156 of about 4,126 (156)

Improved CD4 T cell responses to in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial

Vaccine, 2013
Geert Leroux-Roels, Opokua Ofori-Anyinam, Frédéric Clement   +2 more
exaly  

Non-clinical safety assessment of single and repeated administration of gE/AS01 zoster vaccine in rabbits

Journal of Applied Toxicology, 2017
Eric Destexhe, Nathalie Garcon, Lawrence Segal   +2 more
exaly  

Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models

Lancet, The, 2016
Mark Jit, Azra Ghani, Tom Smith
exaly  

Adjuvant AS01 activates human monocytes for costimulation and systemic inflammation

Vaccine
David H Canaday, Brian Richardson, Mark J Cameron   +2 more
exaly  

Safety and immunogenicity of candidate vaccine M72/AS01 in adolescents in a TB endemic setting

Vaccine, 2015
Angelique Kany Kany Luabeya, Opokua Ofori-Anyinam, Thomas J Scriba   +2 more
exaly  

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

Lancet, The, 2015
exaly